Hypertension therapy: Mixing, matching, and meeting targets

Advances in Therapy

Volumn 21, Issue 2, 2004, Pages 107-122

  Volpe, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiotensin receptor blocker; Cardiovascular risk; Diabetes; Diuretics; Elderly; Systolic blood pressure

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

AFRICAN AMERICAN; AGED; BORDERLINE HYPERTENSION; CARDIOVASCULAR RISK; DIABETES MELLITUS; ETHNOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MICROALBUMINURIA; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW;

EID: 3343010386     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850338     Document Type: Review

References (97)

1. Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
2. Wilber JA, Barrow JG. Hypertension-a community problem. Am J Med. 1972;52:653-663.
3. Weinehall L, Ohgren B, Persson M, et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens. 2002;20:2081-2088.
4. Pannarale G, Gaudio C, Cristina Acconcia M, Cuturello D. Results of antihypertensive treatment by primary and secondary care physicians as assessed by ambulatory blood pressure monitoring. Blood Press Monit. 2000;5:223-226.
5. Deepa R, Shanthirani CS, Pradeepa R, Mohan V. Is the 'rule of halves' in hypertension still valid?-Evidence from the Chennai Urban Population Study. J Assoc Physicians India. 2003;51: 153-157.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
7. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
8. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
9. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-405.
10. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
12. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
13. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
14. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-1010.
15. Vasan RS, Larson mg, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.
16. Glynn RJ, L'Italien GJ, Sesso HDO, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 2002;39:105-110.
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
18. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
19. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701-709.
20. Vasan RS, Larson mg, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-1686.
21. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13:3S-10S.
22. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-1124.
23. Elmer PJ, Grimm RH, Jr., Flack J, Laing B. Dietary sodium reduction for hypertension prevention and treatment. Hypertension. 1991;17:I182-I189.
24. Cohen SJ, Weinberger MH, Fineberg NS, et al. The effect of a household partner and home urine monitoring on adherence to a sodium restricted diet. Soc Sci Med. 1991;32:1057-1061.
25. Mulrow C. Sound clinical advice for hypertensive patients. Ann Intern Med. 2001;135:1084-1086.
26. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157:657-667.
27. Miller ER, 3rd, Erlinger TP, Young DR, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension. 2002;40:612-618.
28. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093.
29. Pickering TG. Lifestyle modification and blood pressure control: is the glass half full or half empty? JAMA. 2003;289:2131-2132.
30. Abernethy DR. Pharmacological properties of combination therapies for hypertension. Am J Hypertens. 1997;10:13S-16S.
31. Antonios TF, Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA. A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril. Hypertension. 1996;27:1325-1328.
32. Julius S. The ALLHAT study: if you believe in evidence-based medicine, stick to it! J Hypertens. 2003;21:453-454.
33. McInnes GT. ALLHAT: a saga of missed opportunities. J Hum Hypertens. 2003;17:373-377.
34. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003;17:81-86.
35. McInnes GT, Yeo WW, Ramsay LE, Moser M. Cardiotoxicity and diuretics: much speculation-little substance. J Hypertens. 1992;10:317-335.
36. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076.
37. Opie L. Angiotensin-Converting Enzyme Inhibitors: The Advance Continues. 3rd ed. Cape Town: University of Cape Town Press; 1999.
38. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13:418-426.
39. Ruilope LM. Recent developments in the treatment of type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2003;17:151-158.
40. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
41. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677-684.
42. American Diabetes Association. Diabetic nephropathy-a position statement. Diabetes Care. 2002;25:S85-S89.
43. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-860.
44. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
45. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
46. Viberti G, Wheeldon NM, for the MARVAL study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation. 2002;106:672-678.
47. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
48. Lindholm L, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
49. Haffner S, Holman R, Califf R. Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Diabetologia. 2003;45:A1-A401.
50. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001; 286:1882-1885.
51. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/{β}- blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
52. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:E28-E32.
53. Luft FC. STOPPING at the CAPPP of good HOPE. Nephrol Dial Transplant. 2000;15:451-452.
54. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
55. Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 2003;21:S25-S30.
56. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
57. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
58. Wang JG, Staessen JA. The benefit of treating isolated systolic hypertension. Curr Hypertens Rep. 2001;3:333-339.
59. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
60. Mallion J, Carretta R, Trenkwalder R, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press. 2003; 12(suppl 1):36-43.
61. Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003;25:2765-2780.
62. Franco R, Goldflus S, MM, Oigman W. Efficacy and tolerability of the combination valsartan/ hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press. 2003;12(suppl 2):41-47.
63. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
64. O'Rourke M, Frohlich ED. Pulse pressure: is this a clinically useful risk factor? Hypertension. 1999;34:372-374.
65. Franklin SS, Khan SA, Wong ND, Larson mg, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354-360.
66. Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol. 2001;88:980-986.
67. Palmieri V, Bella JN, Roman MJ, et al. Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens. 2003;21:781-787.
68. Carretta R, Trenkwalder P, Martinez F, et al. Pulse pressure responses in patients treated with valsartan and hydrochlorothiazide combination therapy. J Int Med Res. 2003;31:370-377.
69. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens. 2000;18:1683-1690.
70. Eichhorn EJ, Domanski MJ, Adams K, et al. Effect of β-blockade on mortality in African-Americans: the β-Blocker Evaluation of Survival Trial. Circulation. 2000;102:II-778.
71. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
72. Peters RM, Flack JM. Salt sensitivity and hypertension in African Americans: implications for cardiovascular nurses. Prog Cardiovasc Nurs. 2000;15:138-144.
73. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189-192.
74. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
75. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
76. Weir MR, Smith DHG, Neutel JM, Bedigian M. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001; 14:665-671.
77. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15:25-32.
78. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995;17:911-923.
79. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088-1096.
80. Palatini P, Malacco E, Di SS, et al. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol. 2002;57:765-170.
81. Higashi Y, Oshima T, Ozono R, et al. Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-hour ambulatory blood pressure monitoring. Hypertension. 1997;30:163-167.
82. Sica DA. What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure? Blood Press Monit. 1999; 4:S9-S16.
83. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1997;278:1745-1748.
84. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000;160:2281-2286.
85. Hagemeister J, Schneider CA, Barabas S, et al. Hypertension guidelines and their limitations-the impact of physicians' compliance as evaluated by guideline awareness. J Hypertens. 2001;19: 2079-2086.
86. Cuspidi C, Michev I, Lonati L, et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens. 2002;16:699-703.
87. Menard J. Critical assessment of combination therapy development. Blood Press Suppl. 1993; 1:5-9.
88. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the Health Survey for England 1998. Hypertension. 2001;38:827-832.
89. Guo JD, Liu GG, Christensen DB, Fu AZ. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Value Health. 2003;6:18-28.
90. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
91. Scandinavian Simvastatin Survival Study Investigators. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
92. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
93. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
94. Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens. 2002;15:917-923.
95. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
96. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7:176-183.
97. van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000;342:1-8.